<DOC>
	<DOCNO>NCT03000517</DOCNO>
	<brief_summary>The emergence spread multi-drug resistant extensively-drug resistant strain Mycobacterium tuberculosis ( MDR/XDR-TB ) pose great threat global TB control elimination , limit treatment success rate worrisome 50 % MDR-TB . Among various factor contribute development drug resistance , low drug exposure well recognize . To overcome , either new drug develop dose currently use therapy optimize , . Fluoroquinolones ( levofloxacin moxifloxacin ) aminoglycosides important drug MDR-TB treatment regimen . Development acquire drug resistance drug could complicate narrow available option , exacerbate pre-XDR XDR-TB . Objective : The main objective prospective clinical study understand pharmacokinetics levofloxacin MDR-TB patient , receive standard dosage ( 750-1250mg ) base body weight correlate drug exposure , treatment outcome . Study design : A prospective pharmacokinetic study Study population : 20 MDR-TB patient Intervention : Patients receive daily oral dosing levofloxacin ( 750-1250mg ) base body weight , MDR-TB treatment regimen Nepal . Main study parameters/end point : The pharmacokinetic parameter ( Vd , CL , AUC etc . ) levofloxacin primary end point study . The Cmax/MIC AUC0-24h/MIC ratio best predictive parameter efficacy levofloxacin treatment estimate . Pharmacokinetics evaluate plasma oral fluid</brief_summary>
	<brief_title>PK Levofloxacin MDR-TB Patients</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis , Multidrug-Resistant</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<criteria>Patient TB , Mycobacterium tuberculosis culture/ Gene Xpert Patient 18 year old newly diagnose previously treat MDRTB Patient sputum smear positive acidfast bacillus sputum smear negative Gene Xpert ( MTB/RIF ) positive , resistant isoniazid rifampicin Patients MDRTB receive levofloxacin part MDRTB regimen Patient neurologic severe extrapulmonary manifestation tuberculosis Pregnant woman breast feed mother MDRTB Patients diminish renal function medication treatment renal disorder Body weight &lt; 35 kg Patients treat aluminium magnesium contain antacid ferrous sulphate , cimetidine probenecid , theophylline , warfarin , zidovudine , digoxin cyclosporine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>levofloxacin</keyword>
	<keyword>multi-drug resistant TB</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>